Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Needham & Company LLC

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $33.00 price objective on the stock. Needham & Company LLC’s price objective indicates a potential upside of 101.10% from the company’s current price.

Several other equities analysts have also weighed in on DAWN. HC Wainwright cut their target price on Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. JPMorgan Chase & Co. upped their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research note on Monday, April 22nd. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $37.67.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ:DAWN opened at $16.41 on Tuesday. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -6.89 and a beta of -1.44. The company has a 50 day moving average of $15.46 and a 200-day moving average of $14.17. Day One Biopharmaceuticals has a one year low of $9.67 and a one year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Equities research analysts anticipate that Day One Biopharmaceuticals will post -2.67 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Adam Dubow sold 3,242 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $49,440.50. Following the sale, the general counsel now directly owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The disclosure for this sale can be found here. Insiders sold 195,247 shares of company stock valued at $3,376,817 over the last quarter. Corporate insiders own 8.40% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its position in shares of Day One Biopharmaceuticals by 130.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after acquiring an additional 1,262 shares in the last quarter. Quest Partners LLC acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth $29,000. Quintet Private Bank Europe S.A. boosted its holdings in Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank boosted its holdings in Day One Biopharmaceuticals by 35.7% during the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Day One Biopharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares during the last quarter. Institutional investors own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.